HomeCompareHALL vs PFE

HALL vs PFE: Dividend Comparison 2026

HALL yields 2500.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HALL wins by $80609755877.32M in total portfolio value
10 years
HALL
HALL
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full HALL calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — HALL vs PFE

📍 HALL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHALLPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HALL + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HALL pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HALL
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, HALL beats the other by $63,520,143,069,556,810.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HALL + PFE for your $10,000?

HALL: 50%PFE: 50%
100% PFE50/50100% HALL
Portfolio after 10yr
$40304877938.71M
Annual income
$37,364,790,040,942,984.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HALL
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
0.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HALL buys
0
PFE buys
0
No recent congressional trades found for HALL or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHALLPFE
Forward yield2500.00%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$80609755877.37M$51.1K
Annual income after 10y$74,729,580,081,858,750.00$27,210.54
Total dividends collected$80198875900.38M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: HALL vs PFE ($10,000, DRIP)

YearHALL PortfolioHALL Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$260,700$250,000.00$9,161$701.38+$251.5KHALL
2$6,370,070$6,091,121.50$8,610$859.79+$6.36MHALL
3$145,912,632$139,096,656.81$8,366$1,081.25+$145.90MHALL
4$3,133,830,814$2,977,704,297.75$8,483$1,405.66+$3133.82MHALL
5$63,122,812,060$59,769,613,088.96$9,084$1,907.24+$63122.80MHALL
6$1,192,683,724,131$1,125,142,315,226.76$10,418$2,732.78+$1192683.71MHALL
7$21,144,559,711,004$19,868,388,126,183.19$13,007$4,193.56+$21144559.70MHALL
8$351,818,906,448,043$329,194,227,557,269.44$18,010$7,005.87+$351818906.43MHALL
9$5,495,491,397,671,320$5,119,045,167,771,913.00$28,216$12,979.89+$5495491397.64MHALL
10$80,609,755,877,367,070$74,729,580,081,858,750.00$51,081$27,210.54+$80609755877.32MHALL

HALL vs PFE: Complete Analysis 2026

HALLStock

Hallmark Financial Services, Inc. underwrites, markets, distributes, and services property/casualty insurance products to businesses and individuals in the United States. The company operates through Specialty Commercial, Standard Commercial, and Personal segments. The Specialty Commercial segment offers primary and excess commercial vehicle insurance products and services; primary and excess liability, excess public entity liability, and E&S package and garage liability insurance products and services; primary and excess commercial property insurance for catastrophe and non-catastrophe exposures; healthcare and financial lines professional liability insurance products and services primarily for businesses, medical professionals, medical facilities, and senior care facilities; and satellite launch property/casualty insurance products and services, as well as various specialty programs. The Standard Commercial segment provides package and monoline property/casualty insurance products and services. The Personal segment offers non-standard personal automobile and renters insurance products and services. It markets its insurance products through independent general agents, retail agents, and specialty brokers. The company was incorporated in 1987 and is headquartered in Dallas, Texas.

Full HALL Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HALL vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HALL vs SCHDHALL vs JEPIHALL vs OHALL vs KOHALL vs MAINHALL vs JNJHALL vs MRKHALL vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.